Top Page
MicroPort Scientific
(0853)
MicroPort Scientific (0853) vs. iShares MSCI Hong Kong ETF (EWH)
MicroPort Scientific Business Overview & Revenue Model
MicroPort Scientific Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.02B | 1.03B | 950.73M | 840.83M | 778.64M | 648.73M |
| Gross Profit | 552.09M | 574.09M | 532.10M | 501.77M | 491.77M | 436.03M |
| EBITDA | -13.83M | -45.30M | -382.54M | -430.26M | -256.35M | -106.87M |
| Net Income | -163.81M | -214.04M | -477.63M | -436.51M | -276.48M | -191.25M |
Balance Sheet | ||||||
| Total Assets | 3.77B | 3.63B | 3.93B | 3.99B | 4.38B | 2.47B |
| Cash, Cash Equivalents and Short-Term Investments | 957.62M | 974.48M | 1.06B | 1.24B | 1.75B | 1.00B |
| Total Debt | 1.76B | 1.69B | 1.70B | 1.47B | 1.24B | 296.31M |
| Total Liabilities | 2.59B | 2.49B | 2.53B | 2.20B | 2.16B | 1.08B |
| Stockholders Equity | 623.12M | 603.47M | 757.82M | 1.14B | 1.49B | 1.13B |
Cash Flow | ||||||
| Free Cash Flow | -83.89M | -158.10M | -430.99M | -600.58M | -505.45M | -143.58M |
| Operating Cash Flow | -27.76M | -49.67M | -231.87M | -343.30M | -257.53M | -23.20M |
| Investing Cash Flow | 16.02M | -149.73M | -376.81M | -412.75M | -655.74M | -148.13M |
| Financing Cash Flow | 37.18M | -97.92M | 434.90M | 273.00M | 1.66B | 846.89M |
MicroPort Scientific Technical Analysis
MicroPort Scientific Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$6.49B | 20.29 | 11.24% | 1.25% | 25.18% | 55.79% | |
62 Neutral | HK$10.67B | 26.67 | 8.69% | 0.77% | 14.56% | 61.60% | |
58 Neutral | HK$6.69B | 30.22 | 11.79% | 1.45% | -5.18% | -9.69% | |
57 Neutral | HK$8.51B | 110.67 | 1.98% | ― | 3.42% | -70.82% | |
54 Neutral | HK$26.07B | -47.93 | -117.51% | ― | 112.97% | 37.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Neutral | $21.88B | -16.56 | -24.77% | ― | -1.04% | 60.66% |
MicroPort Scientific Corporate Events
MicroPort Scientific has released the unaudited financial results for its subsidiary, Shanghai MicroPort Endovascular MedTech (Endovastec), for the nine months ending September 30, 2025. The results show a modest revenue increase of 4.66% compared to the same period in 2024, but a significant decline in profit by 21.80%. Despite the profit drop, Endovastec’s total assets grew by 10.27%, indicating a strong asset base. Investors are advised to exercise caution as these figures are unaudited and do not represent the full scope of the Group’s operations.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation announced that a special resolution to adopt the fifth amended and restated memorandum and articles of association was unanimously approved at the extraordinary general meeting held on October 22, 2025. This change reflects the company’s commitment to updating its governance framework, potentially impacting its operational efficiency and stakeholder engagement.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation announced changes to its board of directors and board committees, effective from September 30, 2025. The company has accepted the resignations of Mr. Hiroshi Shirafuji and Mr. Norihiro Ashida as non-executive directors, who will continue to serve as advisors. Dr. Feng Gu has been appointed as a new non-executive director, bringing extensive experience in financial management and corporate governance. These changes are expected to enhance the company’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation has announced the composition of its board of directors and the roles within its established committees. This announcement provides clarity on the leadership structure, which is crucial for stakeholders to understand the governance and strategic direction of the company.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation has announced an extraordinary general meeting to be held on October 22, 2025, in Shanghai, China. The meeting aims to approve and adopt the fifth amended and restated memorandum of association and articles of association, which will replace the existing ones. This move is expected to streamline the company’s governance structure and enhance operational efficiency, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific has announced a merger agreement involving its subsidiary, MicroPort CardioFlow, and CRM Cayman, which will become an indirect wholly-owned subsidiary of MicroPort CardioFlow. This strategic restructuring aims to enhance MicroPort CardioFlow’s product offerings and global presence in the heart disease market. The merger is expected to improve the financial position of CRM Cayman, optimize the Group’s financing structure, and reduce overall finance costs, benefiting stakeholders by strengthening the company’s market positioning and operational efficiency.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation, a prominent player in the medical device industry, specializes in cardiovascular devices, CRM, orthopedics, and surgical robots, with a significant global presence in over 100 countries.
MicroPort Scientific Corporation announced that the New England Journal of Medicine and the European Society of Cardiology Congress have published findings from the TARGET-FIRST clinical trial, demonstrating that patients with low-risk myocardial infarction require only one month of dual antiplatelet therapy when implanted with Firehawk® Stents, reducing bleeding complications by 54%. This significant recognition highlights the Firehawk® Stent’s potential to transform global clinical practices, emphasizing its high quality, cost-effectiveness, and accessibility, and reinforcing MicroPort’s commitment to advancing cardiovascular treatment strategies.
The most recent analyst rating on (HK:0853) stock is a Buy with a HK$17.20 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation reported a decrease in revenue by 2.2% for the first half of 2025, attributed to external challenges such as geopolitical tensions and market transitions. Despite these challenges, the company narrowed its losses significantly by 65.9% year-on-year, driven by reduced operational costs and strategic divestments of non-core businesses. The company is focusing on optimizing its product mix and expanding its global market presence, with a notable 57.3% growth in its international business revenue. MicroPort is also restructuring its cardiac rhythm management and structural heart disease businesses to enhance its product offerings and market influence, supported by a new strategic investor.
The most recent analyst rating on (HK:0853) stock is a Buy with a HK$17.20 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., a subsidiary of MicroPort Scientific, reported a decline in revenue and profit for the first half of 2025 compared to the same period in 2024. Despite a decrease in financial performance, the company’s total assets and equity showed growth, indicating a mixed impact on its operations and potential implications for stakeholders.
The most recent analyst rating on (HK:0853) stock is a Buy with a HK$17.20 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation has announced a board meeting scheduled for August 29, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and the company’s market positioning.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.
MicroPort Scientific Corporation has announced the partial conversion of its convertible loans, resulting in the issuance of 43,549,965 new shares. This conversion, valued at approximately US$41.5 million, represents 2.34% of the company’s issued shares prior to the conversion and 2.29% post-conversion. The new shares will carry the same rights as existing shares, including dividend rights, which may impact the company’s equity structure and shareholder value.
The most recent analyst rating on (HK:0853) stock is a Hold with a HK$7.30 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.